185 related articles for article (PubMed ID: 22098334)
1. The paradox of triple negative breast cancer: novel approaches to treatment.
Fornier M; Fumoleau P
Breast J; 2012; 18(1):41-51. PubMed ID: 22098334
[TBL] [Abstract][Full Text] [Related]
2. Management of triple negative breast cancer.
Oakman C; Viale G; Di Leo A
Breast; 2010 Oct; 19(5):312-21. PubMed ID: 20382530
[TBL] [Abstract][Full Text] [Related]
3. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
Greenberg S; Rugo HS
Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S20-9. PubMed ID: 20805062
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
Perez EA; Patel T; Moreno-Aspitia A
Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
[TBL] [Abstract][Full Text] [Related]
5. Current treatment options in triple negative breast cancer.
Rodler E; Korde L; Gralow J
Breast Dis; 2010; 32(1-2):99-122. PubMed ID: 21778572
[TBL] [Abstract][Full Text] [Related]
6. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R
Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
[TBL] [Abstract][Full Text] [Related]
7. Directed therapy of subtypes of triple-negative breast cancer.
Carey LA
Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
[TBL] [Abstract][Full Text] [Related]
8. Search for new treatments intensifies for triple-negative breast cancer.
Brower V
J Natl Cancer Inst; 2009 Nov; 101(22):1536-7. PubMed ID: 19880812
[No Abstract] [Full Text] [Related]
9. [Triple-negative breast carcinoma--rewiev of current literature].
Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
[TBL] [Abstract][Full Text] [Related]
10. Directed therapy of subtypes of triple-negative breast cancer.
Carey LA
Oncologist; 2010; 15 Suppl 5():49-56. PubMed ID: 21138955
[TBL] [Abstract][Full Text] [Related]
11. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
Al-Ejeh F; Shi W; Miranda M; Simpson PT; Vargas AC; Song S; Wiegmans AP; Swarbrick A; Welm AL; Brown MP; Chenevix-Trench G; Lakhani SR; Khanna KK
J Nucl Med; 2013 Jun; 54(6):913-21. PubMed ID: 23564760
[TBL] [Abstract][Full Text] [Related]
12. Promising therapeutic options in triple-negative breast cancer.
Bilici A; Arslan C; Altundag K
J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
[TBL] [Abstract][Full Text] [Related]
13. Triple negative breast cancer: a brief review of its characteristics and treatment options.
Griffiths CL; Olin JL
J Pharm Pract; 2012 Jun; 25(3):319-23. PubMed ID: 22551559
[TBL] [Abstract][Full Text] [Related]
14. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategies for triple-negative breast cancer.
Tan AR; Swain SM
Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
[TBL] [Abstract][Full Text] [Related]
16. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
17. Metastatic triple-negative breast cancer.
Rakha EA; Chan S
Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer: novel therapies and new directions.
Pal SK; Mortimer J
Maturitas; 2009 Aug; 63(4):269-74. PubMed ID: 19632796
[TBL] [Abstract][Full Text] [Related]
19. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Kurebayashi J
Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
[TBL] [Abstract][Full Text] [Related]
20. Updates in the treatment of basal/triple-negative breast cancer.
Shastry M; Yardley DA
Curr Opin Obstet Gynecol; 2013 Feb; 25(1):40-8. PubMed ID: 23222093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]